HCW Biologics Inc.
$0.41
▼
-10.7%
2026-04-21 07:16:01
www.hcwbiologics.com
NCM: HCWB
Explore HCW Biologics Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$2.94 M
Current Price
$0.41
52W High / Low
$17.8 / $0.25
Stock P/E
—
Book Value
$-0.8
Dividend Yield
—
ROCE
-4764.31%
ROE
-897.37%
Face Value
—
EPS
$-10.63
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
—
Beta
0.91
Debt / Equity
246.28
Current Ratio
0.11
Quick Ratio
0.11
Forward P/E
-0.66
Price / Sales
45.26
Enterprise Value
$7.31 M
EV / EBITDA
-0.58
EV / Revenue
134.82
Rating
None
Target Price
$2
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Current ratio suggests tighter short-term liquidity.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Monte Rosa Therapeutics, Inc. | $19.81 | — | $1.58 B | — | -14.1% | -16.94% | $25.77 / $3.51 | $3.56 |
| 2. | Kodiak Sciences Inc. | $46.44 | — | $2.87 B | — | -76.6% | -1.49% | $47.41 / $2.34 | $2.55 |
| 3. | Senti Biosciences, Inc. | $1.14 | — | $34.26 M | — | -171.08% | -2.18% | $5.1 / $0.77 | $0.18 |
| 4. | REGENXBIO Inc. | $9.47 | — | $488.82 M | — | -48.13% | -1.07% | $16.19 / $5.85 | $2.02 |
| 5. | AC Immune SA | $2.98 | — | $303.29 M | — | -115.62% | -89.65% | $4 / $1.45 | $0.56 |
| 6. | Lexicon Pharmaceuticals, Inc. | $1.84 | — | $764.74 M | — | -29.8% | -39.72% | $1.95 / $0.49 | $0.3 |
| 7. | Niagen Bioscience, Inc. | $4.87 | 22.44 | $389.99 M | — | 16.53% | 28.35% | $14.69 / $4.16 | $0.96 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0.03 M | 0.02 M | 0.01 M | 0.01 M | 0.39 M | — |
| Operating Profit | -2.95 M | -3.28 M | -3.36 M | -1.69 M | -3.93 M | — |
| Net Profit | 0.72 M | -4.55 M | -1.93 M | -2.2 M | -3.37 M | — |
| EPS in Rs | 0.11 | -0.68 | -0.29 | -0.33 | -0.5 | -4.13 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0.05 M | 2.57 M | 2.84 M | 6.72 M |
| Operating Profit | -11.26 M | -27.63 M | -25.72 M | -15.08 M |
| Net Profit | -7.96 M | -30.02 M | -24.99 M | -14.9 M |
| EPS in Rs | -1.18 | -4.46 | -3.71 | -2.21 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 24.52 M | 30.24 M | 28.51 M | 46.81 M |
| Total Liabilities | 21.76 M | 37.01 M | 15.05 M | 9.38 M |
| Equity | 2.76 M | -6.77 M | 13.46 M | 37.43 M |
| Current Assets | 2.28 M | 5.7 M | 6.4 M | 34.07 M |
| Current Liabilities | 21.06 M | 29.63 M | 8.75 M | 2.96 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -13.39 M | -14.23 M | -22.51 M | -10.39 M |
| Investing CF | 0 M | -0.26 M | 3.8 M | 14.71 M |
| Financing CF | 10.67 M | 15.57 M | -0.01 M | 6.27 M |
| Free CF | -13.39 M | -14.49 M | -28.72 M | -20.66 M |
| Capex | — | -0.26 M | -6.2 M | -10.28 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -9.68% | -57.72% | — | — |
| Earnings Growth % | -20.12% | -67.74% | — | — |
| Profit Margin % | -1169.7% | -879.52% | -221.67% | — |
| Operating Margin % | -1076.41% | -904.96% | -224.32% | — |
| Gross Margin % | 37.38% | 19.72% | 38.48% | — |
| EBITDA Margin % | -1077.53% | -829.62% | -209.1% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2025-04-11 | 1:0.025 |